The University of Manchester, Manchester Academic Health Science Centre, Department of Dermatology, Salford Royal Hospital (Hope), Salford, Manchester, UK.
Drugs. 2012 Oct 1;72(14):1867-80. doi: 10.2165/11634980-000000000-00000.
Psoriasis is a common chronic inflammatory disease of the skin that has a significant impact on quality of life. A small number of systemic therapies are well established in psoriasis management. These have immunosuppressive and/or anti-proliferative effects on the skin and immune system. As understanding of the pathogenesis of psoriasis has advanced over the last 2 decades, there has been clearer appreciation of the genetic, cellular and immunological components of disease expression, which has provided new insight into potential therapeutic targets, including the development of biological therapies. Biologics offer a unique opportunity to block or inhibit specific key components of psoriasis pathogenesis. The introduction of tumour necrosis factor (TNF).α and interleukin (IL)-12/-23 inhibitors has resulted in remarkable clinical responses in patients with severe psoriasis and has led to the development of a range of other cytokine modulators currently undergoing investigation. More recently, research in keratinocyte biology and immune cell function, particularly intracellular signalling, has afforded additional opportunities to develop a range of small-molecule oral preparations that may prove effective in disease control. This paper reviews current and emerging systemic treatments in the management of psoriasis.
银屑病是一种常见的慢性炎症性皮肤病，对生活质量有重大影响。有少数几种全身治疗方法在银屑病的治疗中已得到充分证实。这些方法对皮肤和免疫系统具有免疫抑制和/或抗增殖作用。随着过去 20 年来对银屑病发病机制的理解不断深入，人们对疾病表达的遗传、细胞和免疫成分有了更清晰的认识，这为潜在的治疗靶点提供了新的见解，包括生物疗法的发展。生物制剂为阻断或抑制银屑病发病机制的特定关键成分提供了独特的机会。肿瘤坏死因子 (TNF).α 和白细胞介素 (IL)-12/-23 抑制剂的引入使严重银屑病患者的临床反应显著，导致了目前正在研究的一系列其他细胞因子调节剂的发展。最近，角质形成细胞生物学和免疫细胞功能的研究，特别是细胞内信号转导的研究，为开发一系列可能对疾病控制有效的小分子口服制剂提供了额外的机会。本文综述了目前和新兴的全身治疗方法在银屑病的治疗中的应用。
